Advanced Clinical forms scientific and medical affairs division

Chicago, IL (June 9, 2011) - Advanced Clinical, a leading provider of clinical research talent and solutions, has added a Scientific and Medical Affairs Division to its core client offerings. New divisional service offerings include Pharmacovigilance, Regulatory Affairs, Clinical Pharmacology/Translational Medicine, Medical Monitoring, and Quality Assurance. The Division will also encompass Advanced Clinical's already established and proven Medical Writing and Biometric services.

Heading the Scientific and Medical Affairs Division is Dr. Christina Fleming, Advanced Clinical's newly appointed Executive Vice President, Scientific and Medical Affairs. A highly respected leader in medical affairs and clinical services, Dr. Fleming will build, manage, and lead the Division's full range of offerings.

"We are committed to providing our clients with a full range of specialized services and to ensuring that such services are delivered in conjunction with strong clinical insight and expertise," said Dr. Fleming. "Advanced Clinical's new Scientific and Medical Affairs Division will optimize clinical trials and advance discoveries in clinical research, bringing seamless workflow integration to our clients."

About Advanced Clinical: Advanced Clinical provides talent management, a Clinical Research Organization (CRO), technology solutions, and consulting services to the Life Sciences industry. With 15+ years of experience, Advanced Clinical is an established presence in the clinical research field, providing services specifically for Pharmaceutical, Biopharmaceutical, Biotechnology and Medical Device organizations. Advanced utilizes a value-based, "One Team" approach. To learn more, visit http://www.advancedclinical.com.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.